4/9
09:00 am
spry
ARS Pharmaceuticals (SPRY) is now covered by Northland Securities. They set an "outperform" rating and a $25.00 price target on the stock.
Low
Report
ARS Pharmaceuticals (SPRY) is now covered by Northland Securities. They set an "outperform" rating and a $25.00 price target on the stock.
3/27
08:38 am
spry
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label [Yahoo! Finance]
Neutral
Report
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label [Yahoo! Finance]
3/27
08:00 am
spry
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label
Medium
Report
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label
3/11
12:43 pm
spry
ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines [Seeking Alpha]
Medium
Report
ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines [Seeking Alpha]
3/10
10:09 am
spry
ARS Pharmaceuticals (SPRY) was given a new $26.00 price target by Leerink Partners.
Medium
Report
ARS Pharmaceuticals (SPRY) was given a new $26.00 price target by Leerink Partners.
3/9
05:25 pm
spry
ARS Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
ARS Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
3/9
03:07 pm
spry
ARS Pharmaceuticals Inc (SPRY) Q4 2025 Earnings Call Highlights: Strong Market Entry and ... [Yahoo! Finance]
Low
Report
ARS Pharmaceuticals Inc (SPRY) Q4 2025 Earnings Call Highlights: Strong Market Entry and ... [Yahoo! Finance]
3/9
09:22 am
spry
ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates [Yahoo! Finance]
Medium
Report
ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates [Yahoo! Finance]
3/9
06:39 am
spry
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization [Yahoo! Finance]
Low
Report
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization [Yahoo! Finance]
3/9
06:08 am
spry
ARS Pharmaceuticals GAAP EPS of -$1.74 beats by $0.02, revenue of $84.28M beats by $2.6M [Seeking Alpha]
Low
Report
ARS Pharmaceuticals GAAP EPS of -$1.74 beats by $0.02, revenue of $84.28M beats by $2.6M [Seeking Alpha]
3/9
06:00 am
spry
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization
Low
Report
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization
3/2
12:12 pm
spry
ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? [Yahoo! Finance]
Low
Report
ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? [Yahoo! Finance]
2/27
06:26 am
spry
ARS Pharmaceuticals (SPRY) was upgraded by Zacks Research from "strong sell" to "hold".
Low
Report
ARS Pharmaceuticals (SPRY) was upgraded by Zacks Research from "strong sell" to "hold".
2/23
08:00 am
spry
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences
Low
Report
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences
2/13
11:28 pm
spry
ARS Pharmaceuticals: Climbing Neffy Sales And Global Expansion Could Re-Rate The Stock [Seeking Alpha]
Medium
Report
ARS Pharmaceuticals: Climbing Neffy Sales And Global Expansion Could Re-Rate The Stock [Seeking Alpha]
2/10
08:00 am
spry
ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
Low
Report
ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
2/2
08:00 am
spry
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing =15 kg to <30 kg
Low
Report
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing =15 kg to <30 kg
1/29
07:41 am
spry
ARS Pharmaceuticals (NASDAQ:SPRY) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Low
Report
ARS Pharmaceuticals (NASDAQ:SPRY) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
1/23
05:06 am
spry
ARS Pharmaceuticals (NASDAQ:SPRY) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
ARS Pharmaceuticals (NASDAQ:SPRY) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/21
10:32 am
spry
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use [Yahoo! Finance]
Low
Report
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use [Yahoo! Finance]
1/21
08:00 am
spry
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
Low
Report
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use